meta
|
evidence
oncology
Living systematic review and meta-analysis
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">Immune checkpoint association</span>
<span style="margin-left: 2em;">nivolumab plus ipilimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">non active control</span>
<span style="margin-left: 1em;">no additional treatment <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
AE (grade 3-4) (1)
AE leading to death (grade 5) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
STIMULI, 0
no additional treatment
nivolumab plus ipilimumab
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
no additional treatment
nivolumab plus ipilimumab
no additional treatment
---
NA
nivolumab plus ipilimumab
NA
---
pathologies: 193 - treatments: 416,864
result logic
×
Study list